- With the company's retail expansion, customers will now have access to its world-class life-saving products across 6000+ retail outlets, popular e-commerce platforms, and the company’s online store without any hassle
- Having disrupted the global market with innovative products that stop uncontrollable bleeding and accelerate wound healing, Axio’s retail entry will also include its newly launched Covid essentials to power through the pandemic.
Bengaluru : Having disrupted the global wound care market through its innovative and life-saving products, Axio Biosolutions, a Bangalore-based integrated wound-care company has announced its entry into retail space. Funded by Ratan Tata, Omidyar Network, Accel and Chiratae Ventures, Axio’s retail move comes in the backdrop of the growing demand for healthcare solutions that align to the changing realities of the pandemic world.
With Axio’s entry into retail, consumers will now have access to the world-class products including ASK+ Kits – consisting of Axiostat and other first-aid dressings that stop uncontrollable bleeding. A perfect kit to keep at home, in a car or even at restaurants and stores for emergency situations.
The retail launch also includes MaxioCel – an advanced wound care dressing to provide comfort and faster healing to patients suffering from chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, post-operative surgical wounds and cavity wounds and the newly launched RESIST+ – Covid essentials manufactured in compliance with WHO standards and pharma regulations. The products in this range include surgical disinfectants, hand sanitizers, multi-surface disinfectant sprays, and alcohol sanitizing wipes among others.
The company has made an initial investment to the tune of INR 3 crores to get into the B2C vertical. Since its launch a few months back, the company has received an overwhelming response for their products and looking at clocking INR 8-10 crore this year. “ At Axio Biosolutions, we have always been driven by the vision to make best-in-class wound care accessible to all. Whether it is products that save the lives of our jawans on the border across 260+ battalions or of medical heroes battling the pandemic, each of our product milestones have been a reflection of our commitment to superior care. Considering the challenges that the pandemic has thrown up for regular households in getting access to the best wound care possible, we realise that now is the time to make our products available at the retail level. In an era of teleconsultations, democratization of critical care products can elevate the overall health and safety ecosystem in the country,” said Leo Mavely, Founder and CEO, Axio Biosolutions.
While the products will be available on the company’s online store ( www.axiobiostore.com ), the company has also partnered with over 6,000+ brick-and-mortar stores as well as popular e-commerce platforms, such as Flipkart, Amazon, Moglix, to deliver its products directly to the end consumer. This is the first phase of its retail expansion. As an increasing number of Indian households adopt the ‘Vocal for Local’ approach, Axio’s pioneering, easy-to-use retail offerings can be the game changer in the current crisis.
“Over the next two months, we will be working towards ensuring that all Indian households will have access to our entire range of wound care products along with Covid essential supplies. Timely home care can make all the difference in critical situations, particularly at a time when our medical system is overburdened. O ur current emphasis is on expanding to newer markets. Over the coming years, we are looking at building more affordable, high-impact, world-class products,” added Leo.
